Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
9 nM 11 nM 15 nM >10 μM >10 μM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M2rVS2tqdmG|ZTDBd5NigQ>? NFPBVWYzPCCq MmTCTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? M{HlVVI1PjRzMUCz
COLO205 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\V[HI6PzJiaB?= M2rTTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO MWmyOFY1OTFyMx?=
U937 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xnc|czKGh? MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN NF20[GczPDZ2MUGwNy=>
MOLM13 M{LyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp NGW2[FNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO Mo\GNlQ3PDFzMEO=
MOLM13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLHO|IhcA>? NVj6WoUxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB{d3KjZnXubYIuemW|aYP0ZY51KGi3bXHuJG1QVE1zMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW62bzDEUmEhf2m2aDDJR|UxKG:oIECuNFk3KM7:TR?= MWWyOFY1OTFyMx?=
MDA-MB-435 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3SSWJHOjRiaB?= MnP0TWM2OD1yLkG2JO69VQ>? Mm\JNVU5ODF6M{G=
K562 NGnmbZlEgXSxdH;4bYMhSXO|YYm= NH7rVI46PiCq MVrEUXNQ M4HLVGlEPTB;MjFOwG0> NFrTd4EzPDRzN{W2Oi=>
DU145 MUjDfZRwfG:6aXOgRZN{[Xl? MmrVPVYhcA>? MlLQSG1UVw>? M{e5SmlEPTB;Nz61JO69VQ>? M1zS[|I1PDF5NU[2
MDA-MB-231 NV7QU4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrrSJF4OSEQvF2= NF7hUGczPCCq Ml\PSG1UVw>? MYPD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= MmHhNlQ1OTd3Nk[=
MCF7 NV76cVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVWosyKM7:TR?= M4DLOlI1KGh? MV3EUXNQ NG\IbopE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> M{HESVI1PDF5NU[2
MCF7 MWDLbY5ie2ViQYPzZZk> M{nVVlUh|ryP MknsNlQhcA>? MlWwSG1UVw>? M1n2bGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NGjyTpUzPDRzN{W2Oi=>
MDA-MB-231 NU\pW4kxU2mwYYPlJGF{e2G7 M4\IXFUh|ryP NWfjeIRzOjRiaB?= NH20UopFVVOR MnPFTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= M13pVFI1PDF5NU[2
MDA-MB-231 M3X0PGZ2dmO2aX;uJGF{e2G7 MWexMVExKM7:TR?= M33XXVI1KGh? NYLRVW9uTE2VTx?= MnHE[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NV:xOoRrOjR2MUe1OlY>
MCF7 NYPXVHlxTnWwY4Tpc44hSXO|YYm= MUGxMVExKM7:TR?= NIXZNJkzPCCq MWfEUXNQ NVHBVYRG\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl M{O5SFI1PDF5NU[2
MDA-MB-231 NITLWJJHfW6ldHnvckBCe3OjeR?= MnTHNE42NTFizszN NWTHepdQPDhiaB?= M1nDOmROW09? MUXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MX[yOFQyPzV4Nh?=
MCF7 NW[2e2J5TnWwY4Tpc44hSXO|YYm= MXqwMlUuOSEQvF2= NXe3UYFPPDhiaB?= NEHTZmJFVVOR NXvL[FFJcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NYi5O4c4OjR2MUe1OlY>
697 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrGeWdKSzVyPUG0PE4{QCCwTR?= NWrhfVR3W0GQR1XS
P12-ICHIKAWA NG\YbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny3TWM2OD17Nj6wOEBvVQ>? MXXTRW5ITVJ?
NB69 NWG4T5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7BcFRGUUN3ME2xOlEvQCCwTR?= M4fibXNCVkeHUh?=
EoL-1 M4r0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zxW2lEPTB;MUi3MlI3KG6P NEnuWZZUSU6JRWK=
BHT-101 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF7OD6yOUBvVQ>? MkXCV2FPT0WU
SK-NEP-1 NWLUNGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\w[|F6UUN3ME2yNlAvODJibl2= M3Pp[XNCVkeHUh?=
MHH-NB-11 NH70cnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWflR4U4UUN3ME2yNlAvOTlibl2= NF22UYlUSU6JRWK=
AsPC-1 NV7ieI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ3Mj61N{BvVQ>? NVrKUVhbW0GQR1XS
ES1 NFHUSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWzdYV2UUN3ME2yOVYvOjVibl2= M4fCc3NCVkeHUh?=
LAMA-84 NXTvZ2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ob3J[UUN3ME2yOVgvOTlibl2= M4rheXNCVkeHUh?=
MOLT-16 M33sVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvITWM2OD1{NUiuOFkhdk1? MXzTRW5ITVJ?
ES7 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHSNXQ{UUN3ME2yO|MvODlibl2= MWPTRW5ITVJ?
KY821 M13UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPnTWM2OD1|MUSuNUBvVQ>? M{fEU3NCVkeHUh?=
RT-112 NILWcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD1|MkGuNFUhdk1? M2HmeHNCVkeHUh?=
HL-60 NFu5U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W4[mlEPTB;M{SwMlY3KG6P NGnGO3RUSU6JRWK=
MOLT-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4Z2lEPTB;M{S1MlE{KG6P Mk\MV2FPT0WU
KARPAS-45 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvFTWM2OD1|N{[uNVYhdk1? MWDTRW5ITVJ?
SK-N-AS NXW3[nFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrpZnlKSzVyPUO4O{45OyCwTR?= M4PzeHNCVkeHUh?=
CTB-1 M4Hsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmyN3BvUUN3ME20NFUvODJibl2= NVrVSmdLW0GQR1XS
NKM-1 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0eZU5UUN3ME20NVEvQDlibl2= MlP3V2FPT0WU
HTC-C3 M4HFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j2e2lEPTB;NEOyMlk2KG6P NWfsSIJ3W0GQR1XS
BE-13 NXzOU5diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLoTWM2OD12NESuNlchdk1? MYDTRW5ITVJ?
KOSC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjnU3VNUUN3ME20OlYvQSCwTR?= M3fNbXNCVkeHUh?=
NB14 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jBfmlEPTB;NEizMlU5KG6P M2fENnNCVkeHUh?=
CAL-27 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj3UplKSzVyPUS5OE42QSCwTR?= NYD1T5ZEW0GQR1XS
H9 NYXkXFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzr[FNLUUN3ME20PVUvPDNibl2= Mmr3V2FPT0WU
RS4-11 NIfWUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTUfYFKSzVyPUWwOE44OyCwTR?= M{XtTHNCVkeHUh?=
PA-1 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC1TWM2OD13MEmuPFYhdk1? NInVPIpUSU6JRWK=
MV-4-11 M3uzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILjdYNKSzVyPUWxN{45PSCwTR?= M13qNHNCVkeHUh?=
OS-RC-2 M{PyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDGfmtxUUN3ME21NlEvPjJibl2= NUSxRXZmW0GQR1XS
RPMI-8226 NXfEVWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176PGlEPTB;NUK2Mlg3KG6P NHL6SmtUSU6JRWK=
HGC-27 M33j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkTWM2OD13NkSuPVkhdk1? NWPvVYZqW0GQR1XS
CHP-212 M3P2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHHTWM2OD13OUOuOVkhdk1? MkPMV2FPT0WU
NB10 M{n2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PhVGlEPTB;NUm5MlE5KG6P Mni2V2FPT0WU
HH NGjQSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P3bGlEPTB;NUm5MlQ{KG6P NW\vbGlNW0GQR1XS
EW-16 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNdlBKSzVyPU[wN{42OiCwTR?= Mn3OV2FPT0WU
ES8 M33NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID3[YNKSzVyPU[wOU4zOSCwTR?= NUW4R4U2W0GQR1XS
HAL-01 M2H1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZyNT62O{BvVQ>? MV3TRW5ITVJ?
A204 NHrFS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZ|Mz65NUBvVQ>? MVTTRW5ITVJ?
MHH-PREB-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLPO2xKSzVyPU[zOk46QSCwTR?= NVzrRlBmW0GQR1XS
EM-2 M3XRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPjTWM2OD14NUCuOlQhdk1? NV7afXp4W0GQR1XS
BV-173 M4\3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPhOlluUUN3ME22OVIvPDhibl2= NXPTd3B{W0GQR1XS
ONS-76 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jFNWlEPTB;Nke3MlgzKG6P NWnPbJU4W0GQR1XS
KM-H2 NUTD[4t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33wcWlEPTB;Nkm1MlU1KG6P MVjTRW5ITVJ?
D-263MG M4\CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SxZmlEPTB;N{G3MlEzKG6P Ml:3V2FPT0WU
ES3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTd{OD65N{BvVQ>? MmjDV2FPT0WU
VA-ES-BJ MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTd|Mj6yO{BvVQ>? NFrDbnZUSU6JRWK=
NBsusSR NVTk[FdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTPUYZoUUN3ME23OFIvQTlibl2= M{[3NXNCVkeHUh?=
NCI-H520 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTd2Nj61NkBvVQ>? M1TYenNCVkeHUh?=
ES5 NULXXYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPZS5VKSzVyPUe1Nk45KG6P M3rKenNCVkeHUh?=
T-24 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTd5OD63NUBvVQ>? NV\CR2VMW0GQR1XS
SW962 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\TdoJKSzVyPUiwPE43OyCwTR?= M3m2NXNCVkeHUh?=
EW-3 M1fLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmycHo{UUN3ME24NFgvPzZibl2= M4TkbHNCVkeHUh?=
RXF393 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fEc2lEPTB;OEGyMlc6KG6P MlK0V2FPT0WU
U251 NX7heGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjMN|V[UUN3ME24NVMvQDhibl2= M33ybXNCVkeHUh?=
CAMA-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPGcmpKSzVyPUizN{46PCCwTR?= NIPjcYxUSU6JRWK=
JVM-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HtSWlEPTB;OEWxMlc5KG6P MlzGV2FPT0WU
COLO-800 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHNTWM2OD16OUeuO|ghdk1? MWPTRW5ITVJ?
OVCAR-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPZcG83UUN3ME25NFAvOSCwTR?= NVzRZYl7W0GQR1XS
LB1047-RCC NWXL[IY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvITWM2OD17MkeuOVYhdk1? MVPTRW5ITVJ?
SW954 M{O4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwXlczUUN3ME25NlkvPDFibl2= MoDyV2FPT0WU
J-RT3-T3-5 M2C4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POOWlEPTB;OUO2MlA3KG6P NVjkZmVRW0GQR1XS
Mewo NYjzOodCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLGfYlKSzVyPUmzOk43KG6P MW\TRW5ITVJ?
NCI-H1770 NUXaUnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTl2MD61OUBvVQ>? NVzlS4ttW0GQR1XS
HO-1-N-1 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PzPWlEPTB;OU[yMlgyKG6P NW\mOZc1W0GQR1XS
HSC-3 NVPNNZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXWOGJKSzVyPUm2Ok41QCCwTR?= MWrTRW5ITVJ?
TYK-nu NHnNe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC4PXRKSzVyPUm5PE4zPSCwTR?= NVmxOIh{W0GQR1XS
KYSE-150 M3rmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXyTWM2OD1zLkCwNFc3KM7:TR?= M1fjVXNCVkeHUh?=
SN12C NHi3XnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwMEC4O|Uh|ryP NES4O3FUSU6JRWK=
MOLT-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojOTWM2OD1zLkCxOFIyKM7:TR?= NInRdnFUSU6JRWK=
TE-11 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnJcnZIUUN3ME2xMlA1QDF{IN88US=> NYLuXFQ1W0GQR1XS
DB NVq4ZmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvOdnZKSzVyPUGuNFczPzNizszN NEXYNGxUSU6JRWK=
CAL-39 NUSzcZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwMEe1NlIh|ryP NHjZPGRUSU6JRWK=
A3-KAW MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyZ49KSzVyPUGuNFg1ODhizszN M4PXenNCVkeHUh?=
CHP-134 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnLO4pTUUN3ME2xMlEyQDB5IN88US=> MlLsV2FPT0WU
TGW NHyyR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMUKzPVUh|ryP Mn7vV2FPT0WU
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwMUOxN|Qh|ryP NV\2XGt1W0GQR1XS
NCI-SNU-1 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnpeVk6UUN3ME2xMlE3OzV2IN88US=> M2Lob3NCVkeHUh?=
CGTH-W-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwMUexPFYh|ryP M1r6enNCVkeHUh?=
MHH-ES-1 M3PPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hi[GlEPTB;MT6xO|k5PiEQvF2= MUnTRW5ITVJ?
LB2241-RCC NV:ycmw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\JfphKSzVyPUGuNVg3OiEQvF2= MX\TRW5ITVJ?
ML-2 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPofGtKSzVyPUGuNlA4OzRizszN M4HYWnNCVkeHUh?=
COR-L23 M3XVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HzcWlEPTB;MT6yNlk{OyEQvF2= M{G1UXNCVkeHUh?=
BFTC-905 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fIXmlEPTB;MT6yOFI3PyEQvF2= MUfTRW5ITVJ?
Hs-578-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXFdpNKSzVyPUGuNlU5OTdizszN NVrnUYlZW0GQR1XS
KG-1 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu5Z5VoUUN3ME2xMlI3Pjh4IN88US=> M1rrWHNCVkeHUh?=
HEL NEC0dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmyUGdxUUN3ME2xMlI6OzN6IN88US=> MlfVV2FPT0WU
A549 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml32TWM2OD1zLkK5N|k6KM7:TR?= M{LoPHNCVkeHUh?=
COLO-741 NWrLd4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XOXmlEPTB;MT6zNlA5QSEQvF2= MoTTV2FPT0WU
PC-3 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6zRnZKSzVyPUGuN|UzOjFizszN NX7QPIFvW0GQR1XS
HOS M3XEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwM{WyPVYh|ryP M2fOUXNCVkeHUh?=
HT-1080 NVz5dWxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn6S2o2UUN3ME2xMlM4PTF7IN88US=> NV:3PIU3W0GQR1XS
TE-8 NFntb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TNZmlEPTB;MT60NVc4PCEQvF2= MnP0V2FPT0WU
BHY MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwNE[5NlMh|ryP M2jPNnNCVkeHUh?=
BB65-RCC NYq3R413T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnaTWM2OD1zLkWwOVI5KM7:TR?= M1fOcXNCVkeHUh?=
HN NFf3[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwNUSwO|Eh|ryP MlL3V2FPT0WU
NCI-H441 NFqwemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP5TWM2OD1zLkW0PVA4KM7:TR?= M2fU[nNCVkeHUh?=
RPMI-8866 NHP6[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\xTWM2OD1zLkW4OVA4KM7:TR?= M2H5SXNCVkeHUh?=
CAL-62 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwNkC4OlIh|ryP NIjTWIlUSU6JRWK=
MG-63 M2nnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNkG4NVMh|ryP M4rZPHNCVkeHUh?=
SK-LU-1 NWHlNlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tie2lEPTB;MT62NlE2OiEQvF2= MXPTRW5ITVJ?
BCPAP NWHWVFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInROJlKSzVyPUGuOlY1PTdizszN NV\SdWN{W0GQR1XS
22RV1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTlTWM2OD1zLk[3PFQ{KM7:TR?= NEPZenNUSU6JRWK=
T47D MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKxPXRsUUN3ME2xMlY5ODZzIN88US=> Mn\rV2FPT0WU
MSTO-211H NI\hOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfDVnJKSzVyPUGuOlk3ODNizszN NGPGcI5USU6JRWK=
DEL M1\xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\wTWM2OD1zLkewNlc{KM7:TR?= MkDFV2FPT0WU
H4 NW\WUYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqU2tKSzVyPUGuO|MzOTJizszN MnfKV2FPT0WU
CAL-51 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwN{S4OVUh|ryP M3vaNHNCVkeHUh?=
ABC-1 M{H4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1zLke4OVgzKM7:TR?= NUCycWpQW0GQR1XS
MZ2-MEL MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3DeIVMUUN3ME2xMlc6PTR{IN88US=> Ml25V2FPT0WU
YKG-1 NUPDdIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLDTWM2OD1zLkixNFYyKM7:TR?= NIfoZ4JUSU6JRWK=
KM12 M3ToUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPyTWM2OD1zLkixOlAzKM7:TR?= NHzLfm1USU6JRWK=
L-363 M4DwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fYcmlEPTB;MT64O|QyOiEQvF2= MVHTRW5ITVJ?
KU812 NXLSc3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwOEmyPFIh|ryP NHK0TXpUSU6JRWK=
LOXIMVI M{nEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyVoRKSzVyPUGuPVEzOjhizszN NVvCW5FMW0GQR1XS
G-401 NULndGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7kSYFKSzVyPUGuPVI1OjhizszN NH;o[5lUSU6JRWK=
SW780 NFHnblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTMTWM2OD1zLkm2NlQ3KM7:TR?= MoTYV2FPT0WU
SW872 NVrBSnl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVZ2lEPTB;MT65PFM{KM7:TR?= MVrTRW5ITVJ?
NB7 NEnFWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrmfWNKSzVyPUGuPVk{OjNizszN MXHTRW5ITVJ?
T98G MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;EfFVKSzVyPUKuNFA3PjZizszN NEXwSmtUSU6JRWK=
SW1710 NEXzfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwME[5OFUh|ryP MnXrV2FPT0WU
NCI-H1573 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPTb2NKSzVyPUKuNFczQThizszN NH7KPVRUSU6JRWK=
KE-37 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vY[WlEPTB;Mj6wPFk2OSEQvF2= NH\ZWWhUSU6JRWK=
786-0 M4rsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJfZZKSzVyPUKuNVU1OzlizszN NH3sVIFUSU6JRWK=
SAS NVjYdGZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PWSWlEPTB;Mj6yNFM4PCEQvF2= M3v3PXNCVkeHUh?=
CAL-54 M2\1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLGOmJNUUN3ME2yMlIxPDF|IN88US=> MWHTRW5ITVJ?
SF268 M2PQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT4RmwzUUN3ME2yMlI{OTJ{IN88US=> NF;LOGlUSU6JRWK=
SW620 M{KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWyS2xKSzVyPUKuNlYyPjlizszN MmrBV2FPT0WU
MN-60 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD1{LkOxNFYh|ryP MWDTRW5ITVJ?
EFO-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD1{LkOyNFU5KM7:TR?= NF7YSZJUSU6JRWK=
NCI-H747 NIT0UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnOO|ZKSzVyPUKuN|IyQTlizszN M1LHdnNCVkeHUh?=
HCC2218 M1\tO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\RTWM2OD1{LkO1N|c1KM7:TR?= NHG4OGdUSU6JRWK=
MIA-PaCa-2 NEjVVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PPSWlEPTB;Mj6zOlQ{PyEQvF2= MYnTRW5ITVJ?
SJSA-1 NXnqXGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwM{e3PVYh|ryP NHnXfYRUSU6JRWK=
RKO MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwM{i0PVYh|ryP NYnie2ZWW0GQR1XS
NB6 M2XJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTKTWM2OD1{LkSwN|c1KM7:TR?= NFfUUJlUSU6JRWK=
ES4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\RTWM2OD1{LkS1OFIzKM7:TR?= MonvV2FPT0WU
EGI-1 NX;NNGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13PWmlEPTB;Mj60Olg5OyEQvF2= NI\LWVRUSU6JRWK=
CTV-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDKTWM2OD1{LkWyO|c{KM7:TR?= NH[5UmVUSU6JRWK=
NCI-H1355 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXPfXZKSzVyPUKuOVU6PTFizszN NYWyTnlYW0GQR1XS
GT3TKB M2\EcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwNUmxPVkh|ryP MmnNV2FPT0WU
SK-HEP-1 NULXVHJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\aXWlEPTB;Mj61PVI3PiEQvF2= NV;YeZhFW0GQR1XS
GAMG NH3HXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwNUmzPVQh|ryP NUPwOWc2W0GQR1XS
SK-MES-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm0TWM2OD1{Lk[xPFA{KM7:TR?= NFHPSVlUSU6JRWK=
RO82-W-1 M3LmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvD[3RKSzVyPUKuOlIxPTdizszN Mn;vV2FPT0WU
ECC10 M{HBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwN{CyNFYh|ryP Mkj5V2FPT0WU
MCF7 NH;ub2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfBdGtKSzVyPUKuO|E1PjRizszN M4qzdXNCVkeHUh?=
D-283MED NXmzWY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5UGlEPTB;Mj63NlQ{KM7:TR?= MnHEV2FPT0WU
RPMI-7951 NFTkSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMRWg2UUN3ME2yMlc2Pjl2IN88US=> MnzJV2FPT0WU
Ramos-2G6-4C10 NGHOR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nzTWlEPTB;Mj63O|A6QSEQvF2= NUjZW5JvW0GQR1XS
KGN MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\MTWM2OD1{LkixPFg1KM7:TR?= NE\UNG9USU6JRWK=
NUGC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwOEK1NFUh|ryP M{\yN3NCVkeHUh?=
NCI-H292 NF;2SVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW4R3hDUUN3ME2yMlg2ODV|IN88US=> M3PDfnNCVkeHUh?=
Becker NHezOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfaXJpKSzVyPUKuPVU5OzJizszN MlPwV2FPT0WU
NCI-H1299 M{K5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG5WIM6UUN3ME2zMlA2OjZ|IN88US=> MVHTRW5ITVJ?
ETK-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwMEW0N{DPxE1? MmnSV2FPT0WU
TK10 NYnOSnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HKcWlEPTB;Mz6yNFE3PSEQvF2= MUjTRW5ITVJ?
VMRC-RCZ NIDicGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj0bXJKSzVyPUOuN|Y1QDhizszN NHnxfIdUSU6JRWK=
YH-13 NGfIRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUdWdKSzVyPUOuOFQxPzlizszN MVvTRW5ITVJ?
DU-145 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvsTWM2OD1|LkS2NlY6KM7:TR?= NF32bXJUSU6JRWK=
SW1088 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTNwNEe0O{DPxE1? MUjTRW5ITVJ?
HOP-92 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHoTWM2OD1|LkWwN|QzKM7:TR?= MV7TRW5ITVJ?
KP-N-YS M4TBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml31TWM2OD1|Lk[yNVM6KM7:TR?= NYK0e5lsW0GQR1XS
NCI-H460 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W1ZWlEPTB;Mz62Olc{KM7:TR?= MVPTRW5ITVJ?
U-2-OS M176dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ZXpNXUUN3ME2zMlczPTN3IN88US=> MYLTRW5ITVJ?
A101D NFTmbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwN{[5N|Yh|ryP MULTRW5ITVJ?
MDA-MB-231 M2jFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXryfJUyUUN3ME2zMlgyQTVzIN88US=> M1nPTHNCVkeHUh?=
IST-MES1 M3jsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2fIhKSzVyPUOuPFMzKM7:TR?= MYfTRW5ITVJ?
COR-L105 NF31eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHnTWM2OD12LkCxPEDPxE1? M4KxTnNCVkeHUh?=
NCI-H1437 NFTiVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwMEKzNFIh|ryP MXrTRW5ITVJ?
CAL-85-1 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXJTWM2OD12LkCyOFYyKM7:TR?= MkH2V2FPT0WU
MZ1-PC MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXWd4RKSzVyPUSuNVg2PTZizszN MoHhV2FPT0WU
VM-CUB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXTd2xKSzVyPUSuN|EzQDRizszN MmLCV2FPT0WU
CHL-1 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KzUWlEPTB;ND6zNlE3QSEQvF2= MojmV2FPT0WU
MDA-MB-361 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwM{OxOVMh|ryP MoLMV2FPT0WU
NCI-H661 NH\q[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnexTWM2OD12LkWwNFkzKM7:TR?= NYPCOFRnW0GQR1XS
EW-11 M3;PPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwNUKyN|Eh|ryP M4PHUHNCVkeHUh?=
BEN NXvwXIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L1WWlEPTB;ND61NlgyPSEQvF2= M37HW3NCVkeHUh?=
BFTC-909 NEnFcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDRXWtKSzVyPUSuOVYzPzVizszN MkDnV2FPT0WU
NCI-H2087 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTD[2RxUUN3ME20MlU5OTZ2IN88US=> Mmr2V2FPT0WU
RVH-421 NVK1XWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4NWlEPTB;ND62OlY6KM7:TR?= NVPOSmxEW0GQR1XS
P30-OHK M2n0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn5UVFKSzVyPUSuOlgxODhizszN MlnzV2FPT0WU
NCI-H28 NF;ZNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwOEG2OlEh|ryP MXTTRW5ITVJ?
ES6 NVrscplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OzXGlEPTB;ND64N|AyPiEQvF2= MUHTRW5ITVJ?
769-P MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTRwOEW5NlYh|ryP MYDTRW5ITVJ?
OE33 NGPIT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLyfohoUUN3ME20Mlg5OTZzIN88US=> MlTlV2FPT0WU
SW982 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwOUWwOlEh|ryP M{PSRXNCVkeHUh?=
A388 M3nyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXGcJVKSzVyPUWuNFI6QDNizszN NVrtV2FxW0GQR1XS
TI-73 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVwME[xPVQh|ryP MXTTRW5ITVJ?
HCT-116 NIrXT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDtTWM2OD13LkC5PFg6KM7:TR?= MXLTRW5ITVJ?
HuP-T3 NXjhfFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfudWpGUUN3ME21MlE5PzB7IN88US=> MmHqV2FPT0WU
G-402 NGjMW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe4Ro5KUUN3ME21MlE6PDF4IN88US=> NUDtcmozW0GQR1XS
NCI-H1792 M2CyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTVwMkS2NlIh|ryP MYfTRW5ITVJ?
NCI-H209 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fUOGlEPTB;NT6yOVk1OiEQvF2= NGji[npUSU6JRWK=
NCI-H1650 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny2TWM2OD13LkOwOlM1KM7:TR?= M{Tu[nNCVkeHUh?=
LCLC-97TM1 NGf1eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTVwM{G4NFgh|ryP M4q5XXNCVkeHUh?=
S-117 NW\pNlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjmbVJYUUN3ME21MlM3QTd4IN88US=> MXrTRW5ITVJ?
GI-ME-N NInxN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDoTWM2OD13LkO5OlgyKM7:TR?= MoDzV2FPT0WU
NCI-H2122 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzkSVNKSzVyPUWuOFk{QTdizszN MoLRV2FPT0WU
NCI-H1793 NWLsOmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLSTo5VUUN3ME21MlY4PTl|IN88US=> M1ToR3NCVkeHUh?=
C2BBe1 M4HIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvMTWM2OD13LkewNFg5KM7:TR?= NVrscJJ5W0GQR1XS
TE-12 M3LqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\NTWM2OD13LkiwOVU3KM7:TR?= NXLrcZZVW0GQR1XS
LCLC-103H NE\0cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwOUG3JO69VQ>? Mm\uV2FPT0WU
A673 NYX1ZlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn2UY9NUUN3ME21MlkyQTN{IN88US=> NUDGOGJNW0GQR1XS
BB30-HNC Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPDTWM2OD13Lkm4N|Yh|ryP MYnTRW5ITVJ?
SF295 NXWyc|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDue5FKSzVyPU[uNFA1OjJizszN M3W1O3NCVkeHUh?=
KU-19-19 M1P1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD14LkCxO|MyKM7:TR?= NH;6T3BUSU6JRWK=
CFPAC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DFOGlEPTB;Nj6wOFQ1OyEQvF2= NGL4bXJUSU6JRWK=
LoVo NXHNc3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1R|dNUUN3ME22MlA2ODZ|IN88US=> MWTTRW5ITVJ?
8505C MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuyXHBKSzVyPU[uNFc2PzNizszN NX\6XYNEW0GQR1XS
GMS-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwMUWwNFIh|ryP NFrmUodUSU6JRWK=
Ca9-22 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwMU[3NUDPxE1? NEO2TW1USU6JRWK=
DOK NYHyNY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZwMkKwO|Ih|ryP NHX3XWhUSU6JRWK=
FADU MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fWW2lEPTB;Nj6yOlA{QSEQvF2= MWPTRW5ITVJ?
BxPC-3 NXu0dWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLlTWM2OD14LkK3N|Ih|ryP M3LYW3NCVkeHUh?=
CAL-33 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpVZpLUUN3ME22MlI6OjBzIN88US=> MnOzV2FPT0WU
SHP-77 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnLTWM2OD14LkOxOVEzKM7:TR?= MYDTRW5ITVJ?
LXF-289 NFzPZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzhZ2JKSzVyPU[uN|M1PTVizszN MXrTRW5ITVJ?
GB-1 NE\kVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwM{iyJO69VQ>? MkDvV2FPT0WU
KS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr5dY1KSzVyPU[uN|g1PDdizszN NIrnV2xUSU6JRWK=
D-502MG NVXtSGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CxUGlEPTB;Nj60NlM4PiEQvF2= NYPrWIllW0GQR1XS
LAN-6 NGrPVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NUGlEPTB;Nj61NVAzOyEQvF2= Mk[2V2FPT0WU
H-EMC-SS M3jsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LiNmlEPTB;Nj61OlE1PyEQvF2= NFn6WphUSU6JRWK=
LC-2-ad NEf6NpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofaTWM2OD14Lk[wNFc3KM7:TR?= MoO1V2FPT0WU
NCI-H1693 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTZwNkKyNVUh|ryP NFTOXG5USU6JRWK=
SK-N-FI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPvTHFRUUN3ME22Mlc2ODR2IN88US=> M1roTHNCVkeHUh?=
D-423MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XQU2lEPTB;Nj63OlEyPyEQvF2= MVTTRW5ITVJ?
KNS-42 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rOfGlEPTB;Nj63PFE6PyEQvF2= MlnaV2FPT0WU
GCT M1rRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnQfnJ4UUN3ME22Mlk{QCEQvF2= Mn7JV2FPT0WU
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KxZWlEPTB;Nz6wOlM{KM7:TR?= MVTTRW5ITVJ?
D-247MG Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Tw[mlEPTB;Nz6wO|g5OSEQvF2= NV;KflFSW0GQR1XS
NCI-SNU-5 NX;ldFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwMUizO|Eh|ryP NInzOZZUSU6JRWK=
TE-6 NUH1c3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e4W2lEPTB;Nz6yNFYxOSEQvF2= MVTTRW5ITVJ?
NOMO-1 NFexUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjJc3hKSzVyPUeuNlIyOjdizszN MYnTRW5ITVJ?
NB17 M{\CPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqyTWM2OD15LkOwN|A6KM7:TR?= MXTTRW5ITVJ?
EW-22 M2n2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G5fWlEPTB;Nz6zOFM1QCEQvF2= MnLOV2FPT0WU
EW-13 M1fT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwM{WxOlIh|ryP MlfHV2FPT0WU
DOHH-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTdwNESwNkDPxE1? M{PJ[3NCVkeHUh?=
TGBC1TKB NYTZbVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzOldKSzVyPUeuOFk5QTlizszN NHXpW3pUSU6JRWK=
GR-ST NI\3XIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXFSpJKSzVyPUeuOVI2QTRizszN NYSyOnhRW0GQR1XS
KYSE-520 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTdwNUW1NVUh|ryP MlvsV2FPT0WU
CAPAN-1 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ITWM2OD15LkW5OVEh|ryP MnnJV2FPT0WU
HCE-4 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vEO2lEPTB;Nz62NlI4QSEQvF2= MVHTRW5ITVJ?
MLMA NIfhVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnMTWM2OD15Lk[yPVU4KM7:TR?= M{DCT3NCVkeHUh?=
HT-144 NV\5cnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\jbHVkUUN3ME23MlY2OzZ6IN88US=> NXL6[mw{W0GQR1XS
KYSE-180 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdwN{GxOlkh|ryP NYPnR5k3W0GQR1XS
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLIXpRDUUN3ME23Mlk2QTdzIN88US=> MlfWV2FPT0WU
IGROV-1 M3H6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDhc2xKSzVyPUeuPVg2PTFizszN MWfTRW5ITVJ?
NCI-H1581 NXLVdmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRThwMEGyJO69VQ>? M1O4[nNCVkeHUh?=
SW1990 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DuRmlEPTB;OD6wOFY2QSEQvF2= MlzvV2FPT0WU
EFM-19 NV7QW201T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfrTWM2OD16LkC4OVQ2KM7:TR?= M37YR3NCVkeHUh?=
OGR-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTuTWM2OD16LkSzNFI{KM7:TR?= NXLne|JYW0GQR1XS
U-118-MG NEfvdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO1TXNKSzVyPUiuOFM1PjNizszN MoPkV2FPT0WU
SK-OV-3 M1XmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDnfXBMUUN3ME24MlQ3PzZ3IN88US=> MYLTRW5ITVJ?
KNS-62 M{j0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17kdGlEPTB;OD61NVc3OSEQvF2= M4P1RXNCVkeHUh?=
GOTO M3;ERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRThwNUe2N|Uh|ryP NYjxbGRiW0GQR1XS
8305C NWG1Z5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v3bGlEPTB;OD63NFQ5PCEQvF2= NH[1OmRUSU6JRWK=
RPMI-2650 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwN{G5OVUh|ryP M4T2cXNCVkeHUh?=
NEC8 M2\RTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrjVlBKSzVyPUiuO|Q{ODdizszN MXnTRW5ITVJ?
KYSE-450 NHrRc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[2TWM2OD16Lki2OVQ5KM7:TR?= NI\lV4JUSU6JRWK=
RMG-I MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rwUGlEPTB;OT6xOFA2QCEQvF2= NG\VSGJUSU6JRWK=
CAKI-1 NYjlOIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvVWnBqUUN3ME25MlMyQTd7IN88US=> MWLTRW5ITVJ?
KYSE-510 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPUotEUUN3ME25MlM2Pzd6IN88US=> NHG2NmJUSU6JRWK=
A4-Fuk NWDL[G9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLxbpNKUUN3ME25MlM3PzBzIN88US=> M1y3e3NCVkeHUh?=
AN3-CA NHjiNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTlwNEW0OFQh|ryP MVzTRW5ITVJ?
SK-N-DZ NFT4[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTlwN{K4OFkh|ryP MYHTRW5ITVJ?
HSC-2 NIjHcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD1TWM2OD17Lke2OlI6KM7:TR?= NEXLWHZUSU6JRWK=
EW-1 NU\mc2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwN{mzOlkh|ryP MoTvV2FPT0WU
D-566MG MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXFTWM2OD17LkizOlY1KM7:TR?= NX7KO21QW0GQR1XS
COLO-792 NH3EZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlwOUi3OFYh|ryP M4e1S3NCVkeHUh?=
TE-10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml60TWM2OD1zMD6wN|k3KM7:TR?= NFzLcoJUSU6JRWK=
NCI-H650 NIXHSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TzfmlEPTB;MUCuOFI5PiEQvF2= NHzydGtUSU6JRWK=
U-266 M1\yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFyLkS1OUDPxE1? NIfrSWVUSU6JRWK=
Detroit562 NYPKbldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFzLkC1NVUh|ryP M2fxZXNCVkeHUh?=
NH-12 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWxTWM2OD1zMT6xOFQ3KM7:TR?= NGexbmJUSU6JRWK=
CO-314 NH2xd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFzLkK4OFIh|ryP NE\RUHVUSU6JRWK=
IST-MEL1 M3PlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDHN3ZWUUN3ME2xNU42OzJ|IN88US=> NVjzW3hsW0GQR1XS
KNS-81-FD M1e3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf5d|FpUUN3ME2xNU42PTJ5IN88US=> M1nnZnNCVkeHUh?=
SW1463 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXzTWM2OD1zMT61PVg6KM7:TR?= M{PsT3NCVkeHUh?=
NCI-H23 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jTc2lEPTB;MUGuOlU2OiEQvF2= MX3TRW5ITVJ?
SK-MEL-2 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS3b49DUUN3ME2xNU44OTl5IN88US=> MULTRW5ITVJ?
NB13 NFTxSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTwTWM2OD1zMj6xOFk2KM7:TR?= NVzTNI46W0GQR1XS
Daoy NE\GNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDfGlEPTB;MUKuNlg2PiEQvF2= NWnjbVFbW0GQR1XS
NCI-H1623 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfuTWM2OD1zMj6zPFAyKM7:TR?= NI\aSoxUSU6JRWK=
NMC-G1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXaTWM2OD1zMj63NVch|ryP MV3TRW5ITVJ?
DK-MG NX3qdmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF{Lkm0PFIh|ryP MkT2V2FPT0WU
TCCSUP NXj1TGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF|LkGyPFQh|ryP NG\CNXNUSU6JRWK=
SCC-15 NFPyN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fo[2lEPTB;MUOuNlY2OSEQvF2= M3vhXHNCVkeHUh?=
NOS-1 NXXudY86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF|LkK4PVMh|ryP MmexV2FPT0WU
RH-1 NHnKTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PWfGlEPTB;MUOuN|A{PyEQvF2= M2TqTnNCVkeHUh?=
SK-MEL-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1c|ZKSzVyPUGzMlM4OjhizszN MlvFV2FPT0WU
NB5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3xTWM2OD1zMz60NFY4KM7:TR?= NUfaeWVlW0GQR1XS
SNU-387 NX7TSFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF|LkWwO|Ih|ryP Ml7TV2FPT0WU
CAL-120 NXjvOWgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TI[mlEPTB;MUOuOlcyQCEQvF2= MX7TRW5ITVJ?
Mo-T NUnhUIR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi0VlhFUUN3ME2xN{44ODdizszN MVzTRW5ITVJ?
LNCaP-Clone-FGC NUPCdnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LDPGlEPTB;MUOuO|k6OiEQvF2= MWnTRW5ITVJ?
CAN NH:zVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInyfJZKSzVyPUG0MlAzQDhizszN NWPWb|VyW0GQR1XS
SK-MEL-30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLjTWM2OD1zND6wOlMh|ryP MXXTRW5ITVJ?
COLO-678 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG2R5N7UUN3ME2xOE4xQDJ{IN88US=> M3vJWnNCVkeHUh?=
SCC-9 NXPJdmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjYVYdmUUN3ME2xOE4yODJzIN88US=> M1uwTnNCVkeHUh?=
KINGS-1 NWr1RVI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnmOlBKSzVyPUG0MlE1ODJizszN MXLTRW5ITVJ?
SL-513 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF2LkG4O{DPxE1? MULTRW5ITVJ?
HLE NYrlUpRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD1zND6zPFUzKM7:TR?= MnTIV2FPT0WU
SW1573 NY\nbGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvzXGpKSzVyPUG0MlQ1OzVizszN MlLyV2FPT0WU
KYSE-140 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF2Lk[zNlch|ryP M4\RWnNCVkeHUh?=
SK-PN-DW NHf5b5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnHT3ZKSzVyPUG0MlgxODFizszN NEXKT4lUSU6JRWK=
A253 M4XEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF3LkC2NlUh|ryP MX3TRW5ITVJ?
CAL-12T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LJbmlEPTB;MUWuOFY3OiEQvF2= Mn7YV2FPT0WU
COLO-679 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TC[WlEPTB;MUWuO|Y5OyEQvF2= NWK1bVBRW0GQR1XS
UACC-257 NWjUT4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXHdW5TUUN3ME2xOk4yOjBzIN88US=> MmLjV2FPT0WU
U-87-MG MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4LkO1NlMh|ryP MYnTRW5ITVJ?
HCC1806 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF4LkewO|Eh|ryP NUnUb2g3W0GQR1XS
NCI-H2170 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuxTWM2OD1zNz6yOFQ5KM7:TR?= MVvTRW5ITVJ?
AGS M{OzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmO3B5UUN3ME2xO{4{QDB6IN88US=> NXLUWZlZW0GQR1XS
MEL-HO NHvmRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF5Lke1NFMh|ryP MkfIV2FPT0WU
SW48 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF5Lke3NVYh|ryP MlrGV2FPT0WU
HuP-T4 NVnjWph7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2bGlEPTB;MUiuNFIxPiEQvF2= M2PxZXNCVkeHUh?=
NCI-H720 NFjxRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\0TWM2OD1zOD6xOFAzKM7:TR?= NGfoOG9USU6JRWK=
RCC10RGB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KyZ2lEPTB;MUiuNVY6PyEQvF2= NFrUNVZUSU6JRWK=
HD-MY-Z NWPy[2tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lse2lEPTB;MUiuNlI2PCEQvF2= MXfTRW5ITVJ?
A427 NGLue21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjLfGdKSzVyPUG4MlUxQTRizszN MYTTRW5ITVJ?
HCC2998 M3jmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTtcWhiUUN3ME2xPE43ODVzIN88US=> M4\FUnNCVkeHUh?=
EPLC-272H NWHE[VlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTKflBKUUN3ME2xPU4xPDN2IN88US=> MkLTV2FPT0WU
C32 NVPuWGxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP3TWM2OD1zOT6wOFUh|ryP NFzL[Y5USU6JRWK=
UMC-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDkTGhWUUN3ME2xPU4zOTJ|IN88US=> NYLCeJJCW0GQR1XS
CaR-1 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOwOW1KSzVyPUG5MlY5ODRizszN M{LGd3NCVkeHUh?=
KYSE-410 M3XZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfKTWM2OD1zOT65NVM6KM7:TR?= MX;TRW5ITVJ?
HuCCT1 NFzPbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJyLk[yPVQh|ryP M3fkdnNCVkeHUh?=
LB996-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJyLkexOlgh|ryP MkiwV2FPT0WU
KYSE-70 M1TXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzTTWM2OD1{MD64NFU6KM7:TR?= NYHiZYpRW0GQR1XS
CAL-72 NH7pSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPrTWM2OD1{MD65NVUh|ryP MljuV2FPT0WU
Capan-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TYPGlEPTB;MkGuNFQyOyEQvF2= NX\FbmhNW0GQR1XS
PANC-08-13 NGG5WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzVUYRPUUN3ME2yNU4zPTF3IN88US=> NVjacm5jW0GQR1XS
SBC-1 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WxOWlEPTB;MkGuN|A5OSEQvF2= MVTTRW5ITVJ?
MFM-223 M1rKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPmeVAxUUN3ME2yNU4{OzR{IN88US=> MYTTRW5ITVJ?
BB49-HNC MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfmR2pxUUN3ME2yNU42PzF4IN88US=> NGS4Z3RUSU6JRWK=
SH-4 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJzLk[2NVgh|ryP MW\TRW5ITVJ?
HuO9 NX7UfY5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PqWGlEPTB;MkGuPVgzPSEQvF2= NXeycXdJW0GQR1XS
AM-38 NWXRUYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ{LkC0PFUh|ryP NX3pdI5EW0GQR1XS
A431 NFTSR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ|LkKxNVkh|ryP MkPYV2FPT0WU
YAPC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfGVWVwUUN3ME2yN{4zPjVzIN88US=> MlroV2FPT0WU
LU-139 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TZTGlEPTB;MkOuOFgxQSEQvF2= NILHPGNUSU6JRWK=
HEC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj4TllKSzVyPUKzMlQ6OzdizszN MVXTRW5ITVJ?
SCC-25 M4TqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ2LkOwNFYh|ryP MYnTRW5ITVJ?
HT-29 NEfY[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nIT2lEPTB;MkSuN|gzOyEQvF2= MkXmV2FPT0WU
PC-14 NGS2fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn3TWM2OD1{ND62OVcyKM7:TR?= NWXhV|E6W0GQR1XS
Calu-6 NWrDNoZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnqTo5KSzVyPUK1MlUxPzFizszN M{HhR3NCVkeHUh?=
SJRH30 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOwbW92UUN3ME2yOU43PDl4IN88US=> M3\0WXNCVkeHUh?=
ChaGo-K-1 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\YTWM2OD1{Nj6xOlI6KM7:TR?= NVHKb3ZZW0GQR1XS
IA-LM M{\nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDx[YxZUUN3ME2yOk4{PjR3IN88US=> M3Ln[HNCVkeHUh?=
GP5d MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wWmlEPTB;Mk[uOFQ6OSEQvF2= M4TlUHNCVkeHUh?=
NCI-H2291 NV;WT5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ4Lk[1OFEh|ryP M3\0VHNCVkeHUh?=
BALL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnOUJpmUUN3ME2yOk46Ozl5IN88US=> M2jxenNCVkeHUh?=
HCC1954 M4rmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:wU2pKUUN3ME2yOk46QDB6IN88US=> NXTjfWVWW0GQR1XS
NCI-H2452 NV\2ZY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nCNGlEPTB;MkeuOFE3OyEQvF2= MWHTRW5ITVJ?
LU-99A M4[4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzR|JKSzVyPUK3MlU2QDJizszN M1nvZXNCVkeHUh?=
NTERA-S-cl-D1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ5LkeyPVkh|ryP NInrUnRUSU6JRWK=
PANC-10-05 M2LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULkfVRyUUN3ME2yO{44Pzd3IN88US=> M4nXPXNCVkeHUh?=
NCI-H2405 NY\VU3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO5TWM2OD1{Nz65N|g4KM7:TR?= NW[zXIJNW0GQR1XS
MDA-MB-415 NWPsSJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ6LkSxN|ch|ryP NXrvVY51W0GQR1XS
NCI-H2342 NFni[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXI[|BKSzVyPUK4MlUzQDFizszN NGHxemZUSU6JRWK=
TGBC24TKB NEi1S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D1XWlEPTB;MkiuO|EyPyEQvF2= NYrjO2w3W0GQR1XS
LU-134-A NXO2TGRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL0THNKSzVyPUK4MlkzPjFizszN Mlv2V2FPT0WU
SCC-4 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG2WYdFUUN3ME2zNU4xPDl2IN88US=> MUjTRW5ITVJ?
Saos-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNzLkmzNFYh|ryP NFHhfIlUSU6JRWK=
RERF-LC-MS NG\ZbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\G[mlEPTB;M{KuPFI{OSEQvF2= M3fad3NCVkeHUh?=
M14 NEjwOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXGPHZKSzVyPUOyMlk4PjRizszN MVjTRW5ITVJ?
HPAF-II MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3tdlJEUUN3ME2zN{42ODFzIN88US=> M2PuNnNCVkeHUh?=
NCI-H1755 NYXiNVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjnS|FKSzVyPUO0MlM{ODVizszN MV3TRW5ITVJ?
D-392MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN3Lki2O|Qh|ryP NGrobndUSU6JRWK=
A704 M{XYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN4LkC0Nlch|ryP NGH6fYlUSU6JRWK=
CP50-MEL-B NWX1NmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPleFBsUUN3ME2zOk4yQTFzIN88US=> MoCxV2FPT0WU
EW-18 M{Hofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN4LkS1NkDPxE1? MVHTRW5ITVJ?
WM-115 NXm4bog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYizdYlyUUN3ME2zOk45ODl7IN88US=> NHLpXoJUSU6JRWK=
LU-65 NVHNfmliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTN5LkG0NVch|ryP M2LGcHNCVkeHUh?=
NCI-H1563 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LRc2lEPTB;M{euNlQ5PCEQvF2= NVLRWmJUW0GQR1XS
DBTRG-05MG NVOzdlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEeyRWtKSzVyPUO4MlA3QTFizszN MYXTRW5ITVJ?
NCI-H630 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTYTWM2OD1|OD60O|E1KM7:TR?= M{LvOnNCVkeHUh?=
NCI-H1155 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jrSmlEPTB;M{muNlQzKM7:TR?= M3zqWnNCVkeHUh?=
OVACR-3 NVHYPVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN7LkmxPVUh|ryP MkfjV2FPT0WU
OAW-42 NX3STVJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSzRnhiUUN3ME20NE41OjV6IN88US=> NGLlUWFUSU6JRWK=
JVM-2 NYfQPZNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:2TWM2OD12MT6yOFE2KM7:TR?= MmPpV2FPT0WU
C3A MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRzLkO0OFch|ryP Mmn3V2FPT0WU
HT55 NIDDVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPxfZNKSzVyPUSyMlI5PDFizszN MVTTRW5ITVJ?
OVCAR-4 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD12Mj6yPVc1KM7:TR?= MYrTRW5ITVJ?
MEG-01 NHvkRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmzUY9KSzVyPUSyMlQ3OTZizszN NEDle4FUSU6JRWK=
NCI-H82 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXnTWM2OD12Mz65PFkzKM7:TR?= M{L1O3NCVkeHUh?=
JEG-3 NFO1[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvGTWM2OD12ND65OFch|ryP M3nwc3NCVkeHUh?=
BPH-1 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfpTWM2OD12Nj6zPVk5KM7:TR?= M2K4NnNCVkeHUh?=
MPP-89 M1Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:0emlEPTB;NEeuNlg6QCEQvF2= M4DZdXNCVkeHUh?=
ALL-PO M{LldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR5LkSxPFgh|ryP NEnyTJJUSU6JRWK=
HT M4f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorJTWM2OD12Nz60PVIh|ryP NXPtWmdMW0GQR1XS
NCI-H2347 NHjLUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rTVGlEPTB;NEiuNFcyPSEQvF2= NXjH[JRbW0GQR1XS
A2780 M2LVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3dGlEPTB;NEmuOFIzQCEQvF2= M{fTVnNCVkeHUh?=
KARPAS-299 NGfWZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR7LkWxNVkh|ryP NVPLR2FVW0GQR1XS
NCI-H1651 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWS5pKSzVyPUS5Mlg5OjFizszN M33DSnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method: Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol <1 mg/mL
In vivo Saline 20 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID